A FIRST-IN-HUMAN FOUR-YEAR FOLLOW-UP STUDY OF DURABLE THERAPEUTIC EFFICACY AND SAFETY OF AAV GENE THERAPY WITH VALOCTOCOGENE ROXAPARVOVEC FOR SEVERE HEMOPHILIA A
暂无分享,去创建一个
M. Ozelo | M. Laffan | K. Pasi | S. Rangarajan | G. Pierce | C. Russell | W. Wong | W. Lester | B. Madan | E. Symington | M. Li | N. Mitchell | B. Kim